Additionally, results from the drug-resistant cells suggest that CDK9 inhibitors, alone or in combination with sublethal doses of BRD4 inhibitor, would be efficacious for patients who are burdened with K-Ras or EGFR mutated lung adenocarcinomas and those who have developed therapy resistance. The gene discussed is KRAS; the disease is lung adenocarcinoma.